Mohit Rawat - 31 Aug 2023 Form 4 Insider Report for Fusion Pharmaceuticals Inc.

Role: President & CBO
Signature: /s/ Maria Stahl as Attorney-in-Fact for Mohit Rawat
Issuer symbol: N/A
Transactions as of: 31 Aug 2023
Net transactions value: $0
Form type: 4
Filing time: 05 Jan 2024, 08:49:37 UTC
Previous filing: 09 Jan 2023
Next filing: 04 Jun 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	FUSN	Common Stock	Award		+12,843			12,843	31 Aug 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	FUSN	Stock Option (Right to Buy)	Award	$0	+135,500		$0.000000	135,500	04 Jan 2024	Common Stock	135,500	$8.44	Direct	F2
transaction	FUSN	Restricted Stock Units	Award	$0	+81,300		$0.000000	81,300	04 Jan 2024	Common Stock	81,300		Direct	F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares were purchased pursuant to the Issuer's 2020 Employee Stock Purchase Plan.
F2	This option vests in 48 equal monthly installments beginning on February 4, 2024.
F3	Each restricted stock unit represents a contingent right to receive one share of common stock of Fusion Pharmaceuticals Inc. for no consideration.
F4	The restricted stock units vest in six equal installments on each of July 4, 2024, January 4, 2025, July 4, 2025, January 4, 2026, July 4, 2026 and January 4, 2027.